Roper Technologies Stock (ROP): The Cash Compounder Fell 37% — Then Bought ITSELF. Our Call: BUY

Roper Technologies (ROP) Q2 2026 — Roper Technologies (ROP), the serial acquirer of niche vertical-market software and tech-enabled businesses (Deltek, Vertafore, Aderant, Neptune, Verathon), reported a clean Q2 2026 beat-and-raise: adjusted EPS of $5.38 topped its $5.25-5.30 guide (+10% YoY) on revenue of $2.11B (+9%, organic +5%), adjusted free cash flow rose 11% to $447M, and management RAISED full-year adjusted EPS guidance for the second time to $22.15-22.30. Ignore the 233% GAAP EPS jump to $11.62 — almost all of it is a one-time, non-cash $835M gain on Roper's Indicor minority stake. The real story: the famous acquirer spent $1.2B buying its OWN stock (3.6M shares; $3.2B / 9.0M shares over three quarters, >8% of the count, back to 2013 levels) while first-half acquisitions collapsed to just $28M vs $2.0B a year ago. The stock (~$355, +5.6% on the print) has fallen ~37% from its $564 high and now trades near 16x earnings — the cheapest in a decade. The catch: organic growth has cooled to 5%, adjusted EBITDA margin slipped 130bps to 38.6%, and the 10% EPS growth is buyback-fueled (adjusted net earnings up only 3%). Our owner-earnings DCF — GAAP understates cash earnings by ~$6.50/share of acquisition amortization — lands fair value near $425, ~20% above the price, even on the cautious organic-only path. Our call: BUY, 4/5. Roper Technologies is one of the market's great quiet compounders — a serial acquirer that has spent 30+ years buying tiny, dominant vertical-market software and tech-enabled businesses (Deltek, Vertafore, Aderant, Frontline, Strata, Neptune, Verathon) and reinvesting their cash into buying more. Q2 2026 was a clean beat-and-raise: adjusted EPS of $5.38 beat the $5.25-5.30 guide (+10% YoY), revenue rose 9% to $2.11B (organic +5%), adjusted free cash flow rose 11% to $447M, and management RAISED full-year guidance for the second time to $22.15-22.30 in adjusted EPS. (Ignore the eye-popping 233% GAAP EPS jump to $11.62 — it's almost entirely a one-time, non-cash $835M gain on Roper's Indicor minority stake, not operating profit.) But the real story of the quarter is a strategy shift: the serial acquirer spent $1.2B buying its OWN stock — 3.6M shares — bringing three-quarter repurchases to $3.2B / 9.0M shares, more than 8% of the company, rolling the share count back to 2013 levels. Meanwhile first-half acquisitions collapsed to just $28M versus $2.0B a year earlier. With its own stock beaten down ~37% from a $564 high to ~$355 (the cheapest ~16x earnings in a decade) and outside deals looking pricey, management decided the best business it could buy was itself. So is this the tell that a wide-moat compounder is finally on sale? We think largely yes — but with eyes open. The blemishes are real: organic growth has cooled to 5%, adjusted EBITDA margin slipped 130bps to 38.6% with operating margins down in all three segments, the 10% EPS growth is buyback engineering (adjusted net earnings grew just 3%), and Roper borrowed $2B on its revolver to fund the buybacks. We value Roper on owner earnings — essentially free cash flow, because GAAP earnings understate cash by ~$6.50/share of acquisition amortization — with a base near $2.6B/year. Even our cautious, organic-only DCF (no heroic new deals) values Roper near $445/share at a 9% discount rate; blending in the margin softness we land at a fair value near $425, roughly 20% above the ~$355 price. The optimistic flywheel-re-engages path is worth well north of that. Our call: BUY, 4/5 — a world-class niche-software compounder, cheaper than it's been in a decade, buying back its own shares while it waits for the next deal. It's a patient accumulate, not a table-pounder: the risk is that growth stays cool and the cheap multiple becomes a value trap, so watch organic growth and segment margins every quarter. We're aligned with (but a touch more measured than) the Street's Buy rating and ~$445 average target. Not financial advice — do your own research. THE CALL: BUY (4/5, A WORLD-CLASS CASH COMPOUNDER, DE-RATED TO A GENUINELY FAIR PRICE) — base-case value ~$425 vs ~$355 today. What to watch: the deal flywheel re-engaging — a large, accretive acquisition that puts Roper's $11B-plus of capital-deployment capacity to work, plus organic growth reaccelerating toward the high-single digits, which would bring back both the growth and the premium multiple; the risk to respect is organic growth slipping below 4% with segment margins still eroding, which would confirm the bear's fear that Roper has grown too big to compound on $21B of goodwill and turn today's cheap multiple into a value trap Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.